These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 28634650)

  • 1. A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo.
    Ueno M; Li CP; Ikeda M; Ishii H; Mizuno N; Yamaguchi T; Ioka T; Oh DY; Ichikawa W; Okusaka T; Matsuyama Y; Arai D; Chen LT; Park YS; Furuse J
    Cancer Chemother Pharmacol; 2017 Aug; 80(2):307-315. PubMed ID: 28634650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer.
    Meyer T; Caplin ME; Palmer DH; Valle JW; Larvin M; Waters JS; Coxon F; Borbath I; Peeters M; Nagano E; Kato H
    Eur J Cancer; 2010 Feb; 46(3):526-33. PubMed ID: 20006921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety profile of nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic cancer treated to disease progression: a subanalysis from a phase 3 trial (MPACT).
    Vogel A; Römmler-Zehrer J; Li JS; McGovern D; Romano A; Stahl M
    BMC Cancer; 2016 Oct; 16(1):817. PubMed ID: 27769210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
    Ramanathan RK; Goldstein D; Korn RL; Arena F; Moore M; Siena S; Teixeira L; Tabernero J; Van Laethem JL; Liu H; McGovern D; Lu B; Von Hoff DD
    Ann Oncol; 2016 Apr; 27(4):648-53. PubMed ID: 26802153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial.
    Tehfe M; Dowden S; Kennecke H; El-Maraghi R; Lesperance B; Couture F; Letourneau R; Liu H; Romano A
    Adv Ther; 2016 May; 33(5):747-59. PubMed ID: 27085323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial.
    Löhr JM; Haas SL; Bechstein WO; Bodoky G; Cwiertka K; Fischbach W; Fölsch UR; Jäger D; Osinsky D; Prausova J; Schmidt WE; Lutz MP;
    Ann Oncol; 2012 May; 23(5):1214-1222. PubMed ID: 21896540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with locally advanced or metastatic pancreatic cancer: a multicenter, randomized phase IIb study.
    Schultheis B; Reuter D; Ebert MP; Siveke J; Kerkhoff A; Berdel WE; Hofheinz R; Behringer DM; Schmidt WE; Goker E; De Dosso S; Kneba M; Yalcin S; Overkamp F; Schlegel F; Dommach M; Rohrberg R; Steinmetz T; Bulitta M; Strumberg D
    Ann Oncol; 2017 Oct; 28(10):2429-2435. PubMed ID: 28961832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer.
    Chiorean EG; Von Hoff DD; Tabernero J; El-Maraghi R; Ma WW; Reni M; Harris M; Whorf R; Liu H; Li JS; Manax V; Romano A; Lu B; Goldstein D
    Br J Cancer; 2016 Jul; 115(2):188-94. PubMed ID: 27351217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.
    Van Cutsem E; Tempero MA; Sigal D; Oh DY; Fazio N; Macarulla T; Hitre E; Hammel P; Hendifar AE; Bates SE; Li CP; Hingorani SR; de la Fouchardiere C; Kasi A; Heinemann V; Maraveyas A; Bahary N; Layos L; Sahai V; Zheng L; Lacy J; Park JO; Portales F; Oberstein P; Wu W; Chondros D; Bullock AJ;
    J Clin Oncol; 2020 Sep; 38(27):3185-3194. PubMed ID: 32706635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
    Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
    Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD
    J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer.
    Chiorean EG; Von Hoff DD; Reni M; Arena FP; Infante JR; Bathini VG; Wood TE; Mainwaring PN; Muldoon RT; Clingan PR; Kunzmann V; Ramanathan RK; Tabernero J; Goldstein D; McGovern D; Lu B; Ko A
    Ann Oncol; 2016 Apr; 27(4):654-60. PubMed ID: 26802160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
    Middleton G; Palmer DH; Greenhalf W; Ghaneh P; Jackson R; Cox T; Evans A; Shaw VE; Wadsley J; Valle JW; Propper D; Wasan H; Falk S; Cunningham D; Coxon F; Ross P; Madhusudan S; Wadd N; Corrie P; Hickish T; Costello E; Campbell F; Rawcliffe C; Neoptolemos JP
    Lancet Oncol; 2017 Apr; 18(4):486-499. PubMed ID: 28259610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
    Von Hoff DD; Ramanathan RK; Borad MJ; Laheru DA; Smith LS; Wood TE; Korn RL; Desai N; Trieu V; Iglesias JL; Zhang H; Soon-Shiong P; Shi T; Rajeshkumar NV; Maitra A; Hidalgo M
    J Clin Oncol; 2011 Dec; 29(34):4548-54. PubMed ID: 21969517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
    Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.
    Louvet C; Labianca R; Hammel P; Lledo G; Zampino MG; André T; Zaniboni A; Ducreux M; Aitini E; Taïeb J; Faroux R; Lepere C; de Gramont A; ;
    J Clin Oncol; 2005 May; 23(15):3509-16. PubMed ID: 15908661
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nab-Paclitaxel plus Gemcitabine Hydrochloride in Patients with Metastatic or Recurrent Pancreatic Cancer - A Single Institution Experience].
    Takeda Y; Katsura Y; Ohmura Y; Sakamoto T; Akiyama Y; Kuwahara R; Morimoto Y; Ishida T; Oneda Y; Murakami K; Naito A; Kagawa Y; Takeno A; Kato T; Tamura S
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1674-1677. PubMed ID: 28133095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.
    Ko AH; Murphy PB; Peyton JD; Shipley DL; Al-Hazzouri A; Rodriguez FA; Womack MS; Xiong HQ; Waterhouse DM; Tempero MA; Guo S; Lane CM; Earwood C; DeBusk LM; Bendell JC
    Oncologist; 2017 Dec; 22(12):1427-e129. PubMed ID: 28935773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study.
    Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.